课题基金 / 基金详情

Optogenetic hub cell control for no seizures, no side-effects temporal lobe epilepsy

Optogenetic hub cell control for no seizures, no side-effects temporal lobe epilepsy
光遗传学中心细胞控制无癫痫发作,无副作用颞叶癫痫
批准号:
9165938
负责人:
IVAN SOLTESZ
金额:
$0.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-12-21 至 2016-02-29

项目摘要

项目成果

IVAN SOLTESZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Temporal lobe epilepsy is the most common form of epilepsy in adults. Currently available anti-epileptic drugs often have significant and debilitating side-effects, and temporal lobe epilepsy frequently becomes resistant to drug therapy, presenting an enormous social and medical problem. The central idea behind the proposed research is that it may be possible to achieve seizure control by transiently inhibiting, only at critical moments, the activity of a low number of unique neurons that may be primarily responsible to triggering seizures in the limbic system. Our recent large-scale computational modeling studies have shown that rare, abnormal, super- connected, hub-like neurons may play a key role in seizure initiation. Subsequently, such hub cells have been demonstrated in the healthy developing hippocampus, and it has been shown that modulation of single hub cells in slices can block the spontaneous bursting activity of the entire network. Here we propose to use novel optogenetic approaches to selectively inhibit abnormal hub-like cells in the dentate gyrus and entorhinal cortex of epileptic adult mice in vivo in order to prevent the hyper-activation of the commissural-associational and temporo-ammonic pathways within the entorhino-hippocampal network specifically at the onset of spontaneous recurrent seizures. Because the manipulation will affect only a few cells in the entire limbic system in a temporally selective manner, effective seizure control may be achieved with minimal effects on the normal information processing of the circuit. If successful, the proposed research will demonstrate a fundamentally novel approach to achieving the goal of “no seizures, no side-effects” for the treatment of epilepsy.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/ncomms2376
发表时间: 2013
期刊: Nature communications
影响因子: 16.6
作者: []
通讯作者:
DOI: 10.1038/nprot.2013.080
发表时间: 2013-08
期刊: Nature protocols
影响因子: 14.8
作者: []
通讯作者:
2019 Inhibition in the CNS Gordon Research Conference and Gordon Research Seminar
  • 批准号:
    9750981
  • 项目类别:
  • 资助金额:
    $2.0万
  • 财政年份:
    2019
  • 负责人:
    IVAN SOLTESZ
  • 依托单位:
Data Science Resource Core
  • 批准号:
    10202750
  • 项目类别:
  • 资助金额:
    $27.37万
  • 财政年份:
    2017
  • 负责人:
    IVAN SOLTESZ
  • 依托单位:
Towards automated phenotyping in epilepsy
  • 批准号:
    9369284
  • 项目类别:
  • 资助金额:
    $19.75万
  • 财政年份:
    2017
  • 负责人:
    IVAN SOLTESZ
  • 依托单位:
Administrative Core
  • 批准号:
    10202749
  • 项目类别:
  • 资助金额:
    $25.35万
  • 财政年份:
    2017
  • 负责人:
    IVAN SOLTESZ
  • 依托单位:
国内基金
海外基金
Hub结构的大样本观测研究
  • 批准号:
    12373029
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2023
  • 负责人:
    周建军
  • 依托单位:
HuB调节炎症因子翻译起始的作用及机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    可月双
  • 依托单位:
细胞衰老过程中HuR与HuB/D对端粒酶活性的竞争性调控作用
  • 批准号:
    82071577
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    唐颢
  • 依托单位:
Free PAR通过ARE结合蛋白HuB参与基因表达调控的作用机制研究
  • 批准号:
    31801182
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    28.0万元
  • 批准年份:
    2018
  • 负责人:
    可月双
  • 依托单位: